


## Octanoyl-L-carnitine-d<sub>3</sub> chloride

<b>Cat. No.:</b>	HY-139392S
<b>CAS No.:</b>	1334532-24-9
<b>Molecular Formula:</b>	C <sub>15</sub> H <sub>27</sub> D <sub>3</sub> ClNO <sub>4</sub>
<b>Molecular Weight:</b>	326.87
<b>Target:</b>	Isotope-Labeled Compounds
<b>Pathway:</b>	Others
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (152.97 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		3.0593 mL	15.2966 mL	30.5932 mL
	5 mM		0.6119 mL	3.0593 mL	6.1186 mL
	10 mM		0.3059 mL	1.5297 mL	3.0593 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Octanoyl-L-carnitine-d<sub>3</sub> (chloride) is the deuterium labeled Octanoyl-L-carnitine chloride<sup>[1]</sup>.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA